Ashfield partners with Asia’s MIMS
Ashfield Healthcare Communications has joined forces with MIMS, a medical communications and drug information provider.
The move sees Ashfield extend its services throughout Asia Pacific, where MIMS has operations in 16 markets across the region.
According to Ashfield, an increasing trend among pharmaceutical companies to conduct launches, scientific meetings and marketing programmes across multiple territories prompted the partnership.
Ashfield Healthcare Communications President Doug Burcin (below) said: “I am delighted with the creation of this strategic partnership. Together, our alliance expands global and local delivery for Ashfield clients to an additional 16 APAC countries and provides unprecedented expertise and cross-collaboration of healthcare communications by both parties.”
Ashfield operates across a further three regions – US, Japan and Europe, but hopes the new alliance will provide further expertise in data-driven market and events management.
MIMS also provides scientific strategy services along with digital medication safety services.
Victor Wright, Chief Client Officer of pharma marketing for MIMS said: “The partnership with Ashfield will form the largest and most comprehensive high-science medical communications network globally.
“The collaboration will provide us both with additional expertise and territories, opening up fantastic opportunities to deliver the best resources for our international pharmaceutical, biotech, and medical devices clients.”
WA Health wins Bayer account
Bayer has appointed WA Health, the specialist health practice of WA Communications, to lead the government affairs brief for its cardiovascular candidate.
The account is being led by WA Health’s director Caroline Gordon, who joined the company from Incisive Health last year.
She said: “This is a flagship win for WA Health and exactly the kind of work we thrive on. We’re delighted to add Bayer to our growing client list. It’s been a really strong few months for the WA team across our specialisms in health and wellbeing and we’re all hugely looking forward to building on this success in 2019.”
This win comes off the back of a successful period for WA Health, having recently secured projects across Sanofi’s oncology portfolio, corporate communications for Takeda and retained work supporting the UK launch of Camurus’ opioid replacement therapy treatment.
Andrew Brown, Bayer’s Government and Industry Affairs Manager said: “We’re very happy to be working with the team at WA on our cardiovascular disease government affairs brief. WA’s ideas really stood out to us during the pitch process and we’re excited to be working with them during this critical phase. We’re confident it’s going to be a strong partnership.”
Lighthouse Medical Communications US relocates
Lucid’s US-based company Lighthouse Medical Communications has moved to new offices based in the financial district of Manhattan, New York.
The move comes as the company celebrates its four-year anniversary, and the company has grown five-fold since its launch.
Jan Steele (pictured below), Lucid COO and Co-Founder, said: “When we established Lighthouse Medical Communications US we knew it would be a challenge. However, the passion and drive of our US team to create magical programmes with their clients has been unrelenting.
“The new offices give Lighthouse the ability to continue to grow by providing a larger office space, more meeting rooms and improved travel connections. It’s definitely an exciting time for the US business, which can now grow its team with even greater confidence.”